Study of LYL314 in Aggressive Large B-Cell Lymphoma
Phase 1/2
270
about 8.1 years
18+
30 sites in CA, CO, GA +16
About this study
Researchers are testing a new treatment called LYL314 for people with aggressive large B-cell lymphoma. The trial will evaluate the safety and effectiveness of this treatment, which targets CD19 and CD20 cells.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cyclophosphamide
- 2.Take Fludarabine
- 3.Take LYL314
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine
infusion
Primary: Phase 1: Evaluate the safety and tolerability of a single dose of ronde-cel administered as a single agent, Phase 2: Estimate the efficacy of ronde-cel, as measured by overall response rate (ORR)
Secondary: Phase 1: Evaluate the pharmacokinetics of ronde-cel when administered as a single agent, Phase 2: Evaluate the pharmacokinetics of ronde-cel when administered as a single agent, Phase 2: Evaluate the safety and tolerability of a single dose of ronde-cel administered as a single agent
Oncology